Zawsai Aung
Payments from drug & device makers
Across 77 payments — averaging $19.45 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Gilead$322
- AbbVie$283
- Shield Therapeutics Inc$121
- Lilly USA, LLC$106
- AstraZeneca$103
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$90
- plus $473 from 13 others
What the payments were for
- Food & beverage$1,498100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Gilead | 15 | $322 |
| AbbVie | 17 | $283 |
| Shield Therapeutics Inc | 6 | $121 |
| Lilly USA, LLC | 6 | $106 |
| AstraZeneca | 5 | $103 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 3 | $90 |
| Merck | 4 | $77 |
| Boehringer Ingelheim | 3 | $47 |
| Daiichi Sankyo Inc. | 2 | $46 |
| Phathom Pharmaceuticals, Inc. | 2 | $41 |
| GSK | 2 | $38 |
| Insulet Corporation | 2 | $37 |
| Pfizer | 2 | $36 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 2 | $31 |
| Bayer | 2 | $30 |
| Corcept Therapeutics | 1 | $25 |
| UCB, Inc. | 1 | $23 |
| Recordati_rare_diseases_inc. | 1 | $22 |
| Exact Sciences | 1 | $18 |
How this compares
$1,498 in reported general payments places this provider in the 75th percentile of 8,883 family providers in New York.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 104 | $70,030 |
| FarxigaDapagliflozin Propanediol | 75 | $53,199 |
| JardianceEmpagliflozin | 30 | $34,869 |
| OzempicSemaglutide | 33 | $33,494 |
| KerendiaFinerenone | 31 | $26,408 |
| JanuviaSitagliptin Phosphate | 36 | $24,406 |
| EliquisApixaban | 27 | $23,768 |
| EntrestoSacubitril/Valsartan | 13 | $14,110 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 14 | $11,470 |
| Incruse ElliptaUmeclidinium Bromide | 30 | $10,851 |
| DapagliflozinDapagliflozin Propanediol | 18 | $9,077 |
| TradjentaLinagliptin | 13 | $8,562 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 20 | $8,372 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 246 | $6,850 |
| VascepaIcosapent Ethyl | 18 | $6,246 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Incruse Ellipta, Anoro Ellipta | $38 | $89,252154 claims |
| AstraZenecaFarxiga, Breztri Aerosphere, Symbicort | $103 | $68,517108 claims |
| Boehringer IngelheimJardiance, Tradjenta | $47 | $43,43243 claims |
| BayerKerendia | $30 | $26,40831 claims |
| MerckJanuvia | $77 | $24,40636 claims |
| PfizerEliquis | $36 | $23,76827 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 8,883 family providers in New York.
Other family in Utica
- Jenna PawloskiUtica$62K
- Nicolette HaleyUtica$19K
- Christina NalboneNew York$197K
- Casey GrilloNew York$191K
- Suzanne WilsonIthaca$179K
- Jonathan LesuerSyracuse$172K
- Sheri HillNorth Syracuse$165K
- Cathrine CurtinBronxville$155K
- Mary Sullivan-WhalenNew York$137K
- Sarah AljahmiRockville Centre$87K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.